文献速递免疫规划传染病防控与疫情报告

2016/17年英国成人和儿童流感季末疫苗有效性

End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17.
PubMed 文献 · Euro Surveill · 2017-01-01

英国2016/17流感季采用检测阴性病例对照设计评估流感疫苗有效性。调整后疫苗有效性对全部流感为39.8%(95%CI:23.1至52.8),18-64岁为40.6%(95%CI:19.0至56.3),≥65岁无显著有效性;2-17岁接种四价减毒活疫苗的有效性为65.8%(95%CI:30.3至83.2)。

要点

  • 2016/17季末调整后疫苗有效性对全部流感为39.8%(95%CI:23.1至52.8)。
  • 18-64岁调整后疫苗有效性为40.6%(95%CI:19.0至56.3),≥65岁无显著有效性。
  • 2-17岁接种四价减毒活疫苗调整后有效性为65.8%(95%CI:30.3至83.2)。

核心结论

  • 研究结果持续支持儿童疫苗规划的推广,同时需要持续评估。
  • 保护≥65岁人群的有效干预措施仍然重要。

研究设计与样本

  • 采用检测阴性病例对照设计,在初级保健中估计疫苗对实验室确诊流感的有效性。

主要发现

  • 调整后季末疫苗有效性对全部流感为39.8%(95%CI:23.1至52.8)。
  • 18-64岁调整后疫苗有效性为40.6%(95%CI:19.0至56.3)。
  • ≥65岁无显著调整后疫苗有效性。
  • 2-17岁接种四价减毒活疫苗的调整后疫苗有效性为65.8%(95%CI:30.3至83.2)。

关键数值与推荐

  • 调整后疫苗有效性对全部流感为39.8%(95%CI:23.1至52.8)。
  • 18-64岁调整后疫苗有效性为40.6%(95%CI:19.0至56.3)。
  • 2-17岁接种四价减毒活疫苗调整后疫苗有效性为65.8%(95%CI:30.3至83.2)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IntroductionThe United Kingdom is in the fourth season of introducing a universal childhood influenza vaccine programme. The 2016/17 season saw early influenza A(H3N2) virus circulation with care home outbreaks and increased excess mortality particularly in those 65 years or older. Virus characterisation data indicated emergence of genetic clusters within the A(H3N2) 3C.2a group which the 2016/17 vaccine strain belonged to. Methods: The test-negative case-control (TNCC) design was used to estimate vaccine effectiveness (VE) against laboratory confirmed influenza in primary care. Results: Adjusted end-of-season vaccine effectiveness (aVE) estimates were 39.8% (95% confidence interval (CI): 23.1 to 52.8) against all influenza and 40.6% (95% CI: 19.0 to 56.3) in 18-64-year-olds, but no significant aVE in ≥ 65-year-olds. aVE was 65.8% (95% CI: 30.3 to 83.2) for 2-17-year-olds receiving quadrivalent live attenuated influenza vaccine. Discussion: The findings continue to provide support for the ongoing roll-out of the paediatric vaccine programme, with a need for ongoing evaluation. The importance of effective interventions to protect the ≥ 65-year-olds remains.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Pebody R, Warburton F, Ellis J, et al. End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17. Euro Surveill. 2017. PMID: 29113630. doi:10.2807/1560-7917.ES.2017.22.44.17-00306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。